Business Context and Reporting Period
This Form 8-K filing by NantKwest, Inc. (not Immunitybio, Inc.) covers events occurring on June 10, 2020, specifically the company's 2020 Annual Meeting of Stockholders. The registrant is a Delaware corporation trading on the Nasdaq Global Select Market under the symbol NK.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on corporate governance and equity plan amendments.
Material Changes and Voting Results
Stockholders approved three key matters at the Annual Meeting, where approximately 91.31% of outstanding shares were represented:
- Equity Plan Amendment: The 2015 Equity Incentive Plan was amended to increase the number of reserved common stock shares by 3,000,000. This received 74,555,760 votes for, 2,219,752 against, and 600,293 abstentions.
- Election of Directors: All seven nominees were elected to serve until the 2021 annual meeting. Notable nominees included Patrick Soon-Shiong, MD, and Barry J. Simon, MD.
- Auditor Ratification: The appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020, was ratified with 89,622,646 votes for.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management outlook, or discussion of risks and contingencies. It notes that the full text of the Amended and Restated 2015 Equity Incentive Plan will be filed as an exhibit to the Form 10-Q for the period ended June 30, 2020.
Investor Verification Checklist
- Verify the total number of shares reserved under the amended 2015 Equity Incentive Plan in the upcoming Form 10-Q.
- Confirm the tenure and specific roles of the newly elected directors.
- Review the full text of the Equity Incentive Plan amendment for details on vesting schedules and eligibility.
- Note the discrepancy in the request metadata regarding the company name; the filing is for NantKwest, Inc., not Immunitybio, Inc.